INCY Stock Recent News
INCY LATEST HEADLINES
Incyte (INCY) came out with a quarterly loss of $1.82 per share versus the Zacks Consensus Estimate of $0.78. This compares to earnings of $0.99 per share a year ago.
On Incyte's (INCY) second-quarter 2024 earnings call, investors' focus is likely to be on the sales performance of its lead drug, Jakafi, which has been facing stiff competition.
Incyte (INCY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Incyte (INCY) and Myriad Genetics (MYGN). But which of these two companies is the best option for those looking for undervalued stocks?
Incyte (INCY) jumped 19.6% in the past three months as investors appreciated the stock grants and buyback plan.
Every investment category must answer the big question, why? For undervalued biotech stocks, it comes down to advantaging a supremely relevant sector without paying full price.
In recent months, Incyte's management has continued to delight investors by accelerating the pace of development of its anti-inflammatory treatments. On May 30, 2024, Incyte announced the completion of its acquisition of Escient Pharmaceuticals for $750 million. Sales of Opzelura, one of the company's gems, totaled $85.7 million in the first quarter of 2024, up 51.4% year-on-year.
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte Announces Final Results of Tender Offer.
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte Announces Preliminary Results of Tender Offer.
Dublin, June 07, 2024 (GLOBE NEWSWIRE) -- The "Malignant Mesothelioma - Pipeline Insight, 2024" report has been added to ResearchAndMarkets.com's offering.